Gonadotropin-releasing hormone agonist improves the efficiency of controlled ovarian hyperstimulation/intrauterine insemination

Carol L. Gagliardi; Adelina M. Emmi; Gerson Weiss; Cecilia L. Schmidt

doi:10.1016/s0015-0282(16)54303-9

Gonadotropin-releasing hormone agonist improves the efficiency of controlled ovarian hyperstimulation/intrauterine insemination

Carol L. Gagliardi, Adelina M. Emmi, Gerson Weiss, Cecilia L. Schmidt

In: Fertility and Sterility · 1991 · vol. 55(5) , pp. 939–944 · doi:10.1016/s0015-0282(16)54303-9 · PMID:1902421 · W2465144380

article OA: closed CC0 ⤵ 2 in-corpus citations

View on OpenAlex View on PubMed View at publisher

⚙ AI-generated summary by claude@2026-06, 2026-06-13 ⓘ

This study investigated whether a gonadotropin-releasing hormone agonist improves the efficiency of controlled ovarian hyperstimulation combined with intrauterine insemination.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectiveLeuprolide acetate (LA) has improved the efficiency of human menopausal gonadotropins (hMG) in in vitro fertilization cycles. We hypothesized that the combination of LA/hMG/intrauterine insemination (IUI) would be more efficacious than hMG/IUI cycles.DesignDuring an 18-month period, all patients completing either a hMG/IUI cycle (group I) or a LA/hMG/IUI cycle (group II) had the characteristics and outcomes of their stimulation cycles assessed. The groups were not prospectively randomized.SettingReferral center at a tertiary care hospital.PatientsOne hundred twenty three patients in group I completed 219 cycles, and 64 patients in group II completed 102 cycles. Twenty-eight of the patients who failed to conceive with hMG/IUI were advanced to group II.Main outcome measuresPregnancy/IUI is compared between the two groups.ResultsGroup II demonstrated significantly greater clinical pregnancy/IUI than group I (26.5% and 16.0%, respectively, P less than 0.05), as well as a higher live birth/IUI (21.6% and 12.8%, respectively, P less than 0.05). No difference was present in the rate of fetal wastage or multiple births.ConclusionsIn our patients with recalcitrant infertility, the addition of a gonadotropin-releasing hormone agonist to hMG/IUI improved the pregnancy rate, without increasing the rate of multiple births or fetal wastage.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

Dating the Endometrial Biopsy 1950

Cited by (2)

References (28)

Dating the Endometrial Biopsy via openalex
doi:10.1016/s0140-6736(84)90932-2 via openalex
doi:10.1016/s0015-0282(16)60733-1 via openalex
doi:10.1016/s0015-0282(16)53209-9 via openalex
doi:10.1016/s0015-0282(16)59536-3 via openalex
doi:10.1016/s0015-0282(16)59669-1 via openalex
W2430367416 via openalex
W4285719527 via openalex
doi:10.1016/s0015-0282(16)60122-x via openalex
doi:10.1016/s0015-0282(16)59414-x via openalex
doi:10.1016/s0015-0282(16)59052-9 via openalex
doi:10.1016/s0015-0282(16)48969-7 via openalex
doi:10.1016/0020-7292(88)90288-3 via openalex
doi:10.1016/s0015-0282(16)59583-1 via openalex
doi:10.1016/s0015-0282(16)59825-2 via openalex
doi:10.1016/s0015-0282(16)59115-8 via openalex
doi:10.1016/s0015-0282(16)59655-1 via openalex
doi:10.1016/s0015-0282(16)59826-4 via openalex
doi:10.1016/s0015-0282(16)60453-3 via openalex
doi:10.1016/s0002-9378(88)80089-9 via openalex
doi:10.1016/s0015-0282(16)53825-4 via openalex
doi:10.1016/0020-7292(91)90680-4 via openalex
doi:10.1016/s0015-0282(16)49647-0 via openalex
doi:10.1159/000293320 via openalex
doi:10.1007/bf01130828 via openalex
doi:10.1016/s0015-0282(16)43634-4 via openalex
doi:10.1016/s0015-0282(16)59822-7 via openalex
doi:10.1016/s0015-0282(16)60851-8 via openalex

Cited by (2)

Source provenance

openalex: last seen: 2026-05-13T18:38:08.563906+00:00

License: CC0 · commercial use OK

[1] Dating the Endometrial Biopsy 1950